U.S. markets open in 5 hours 41 minutes

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
73.27+0.09 (+0.12%)
At close: 4:00PM EST
Sign in to post a message.
  • W
    WealthMastersClub1
    $GILD conversation
    The only company conducting a late stage clinical trial for the treatment of Refractory Ascites due to Liver Cirrhosis $NVS $NVO $ABBV $ICPT $TBIO
    https://www.youtube.com/watch?v=xxzTsexijPU&feature=youtu.be
  • H
    Harvey
    Anyone know why the stock price cratered in 2016?
    Bullish
  • b
    blackoutbuzz
    NVO finally did it. They bought EMIS for $1.8B. Gotta wonder though... why did they wait so long and end up paying this whopping big amount for a technology that was clearly essential to their new drug.

    @@@With its stock near record highs, Denmark's Novo Nordisk (NVO) on Friday announced an agreement to buy an oral drug delivery company for $1.8 billion, and NVO stock edged higher early.

    Novo Nordisk is acquiring Emisphere Technologies, which has developed proprietary drug delivery technologies to convert injectable therapeutics into oral therapeutics. Many patients would rather take a pill than get an injection, but it can be technically challenging to deliver medicine in tablet form. Novo Nordisk already licenses some of Emisphere's Eligen SNAC technology. It's used for an oral version of Novo Nordisk's type 2 diabetes drug Rybelsus.

    https://www.investors.com/news/technology/nvo-stock-up-novo-nordisk-announces-1-8-billion-acquisition/?src=A00220
    Novo Nordisk, trading near record highs, announced it would buy a maker of proprietary oral drug delivery technology for $1.8 billion; NVO stock rose.
    Novo Nordisk, trading near record highs, announced it would buy a maker of proprietary oral drug delivery technology for $1.8 billion; NVO stock rose.
    www.investors.com
  • H
    Hguy
    $AEZS conversation
    $AEZS $NVO new 2019 share repurchase programme
    The Board of Directors has approved a new share repurchase programme of up to DKK 15 billion to be executed
    during the coming 12 months. The total programme may be reduced in size, in case of a significant bolt-on
    acquisition during 2019.
    https://www.novonordisk.com/bin/getPDF.2233033.pdf
  • D
    David
    In case anyone isn't aware here, check out little EMIS. Novo (NVO) contracts with them to use their pill technology for the recently announced very positive ph3 data, and for the next 9 ph3 trials anticipated to complete and have data released over the course of 2018.
  • k
    ken.
    $MNKD conversation
    $sny and $nvo Don't sweat this actors acting before the house special committee on aging discussing diabetes research funding. Likely helps you. This video was published by mnkd. Since released 10 mos ago sales of poor selling Afrezza, that's not a substitute for long acting insulin and hasn't yet started FDA mandated 8-10K patient FDA, have continued their downward spiral. Since it's a mnkd video one must wonder what actor received to give the brief Afrezza bleeb that had nothing to do with focus of committee.

    Underwater mnkd pumpers are desperate and afraid.
    House of Cards actor, Paul Sparks, speaks to Congress on diabetes funding and makes mention of his experience with inhaled insulin. JDRF Children’s Congress ...
    House of Cards actor, Paul Sparks, speaks to Congress on diabetes funding and makes mention of his experience with inhaled insulin. JDRF Children’s Congress ...
    www.youtube.com
  • A
    Arnold
    Bagsværd, Denmark, 20 March 2019 -Novo Nordisk today announced the submission
    of two New Drug Applications (NDAs) to the US Food and Drug Administration
    (FDA) for oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1)
    analogue in a tablet, as well as a supplemental NDA (sNDA) for once-weekly
    Ozempic(semaglutide).
  • D
    Dan
    Has everyone seen this?:

    Novo Nordisk: Rybelsus ICER Report Justifies Price, Januvia The Likely Victim $NVO https://seekingalpha.com/article/4312919
    Novo Nordisk is a leader in the GLP-1 receptor agonist space. Recent FDA approval of Rybelsus (Semaglutide) marks the first oral GLP-1 receptor agonist to hit t
    Novo Nordisk is a leader in the GLP-1 receptor agonist space. Recent FDA approval of Rybelsus (Semaglutide) marks the first oral GLP-1 receptor agonist to hit t
    seekingalpha.com
  • c
    charlie
    Hey Insiders, will Novo soon announce the purchase of EMIS? There is much speculation on how this makes so much sense. EMIS stock is rising tremendously and its felt the buyout may be driving it.
  • K
    KenLongernow
    $MNKD conversation
    $nvo $sny for a great laugh and good short opportunity read mnkd 2Q18 10Q. Replete w/ mgmt statements of having doubts about remaining in business. At end of June had about 26M in cash left has major debt payments due. Check out a seeking alpha article about their only drug, afrezza a flop of historic proportions, being worthless. Individually, just 1 NVO diabetes med sells more in 4 days than mnkd has sold of afrezza in 4 years. Most recent script data for this flop is Nrx = 276 Refills = 298
  • C
    C
    Surprised nobody's commented on NVO hitting ATHs while the rest of the market is down. Great company, great science, great stock!
  • y
    yoni f
    I am buying long term. A weight loss medical procedure, that is worth billions. Heart diseases, cancer, diabetes, and many other diseases are link to overweight. Find very estrange the lack ok of eyes on this. Anyway long term.
  • K
    KenLongernow
    $MNKD conversation
    After doing some research I found that not only does Victoza get more scripts in 1 wk than afrezza has got in more than 4 years, but Victoza now FDA-approved to reduce the risk of heart attack, stroke, and heart-related death. Victoza is a diabetes medicine that reduces heart disease and stroke! Afrezza, the biggest flop in diabetes history has more FDA complaints per sales than any other diabetes drug. No lawsuits have advertised because it's not worth the time or expense to plantiff's attorneys. MNKD hasn't done FDA required safety study that was ordered almost 5 years ago. Afrezza prescription numbers point to it's danger and serious complications. Remember also they got caught by FDA in a fraud about it's risks and safety. $nvo
  • M
    Marc
    See EMIS for the oral semiglutide enabling tech, royalty oppty. and perhaps buyout.
  • E
    Eric
    NVO investors should take a look at $GERN. Possible tremendous upside with their JNJ collaboration. Thank you for your time NVO investors.
  • B
    Barry
    I think NVO should buy out EMIS before they have the chance to introduce their product to other companies !
  • T
    Techfan20
    NVO leveraging EMIS technology, brilliant.
    Bullish
  • D
    Dionysos
    Why is this board so quiet? I bought NVO a few months ago and I just began investing last year. Feels like a quality company and it's been doing well. Isn't diabetes meds like infinite money maker?
    Bullish
  • C
    C
    Rybelsus approved!
  • b
    blackoutbuzz
    NVO is trading at the same price it was 5 years ago.Not very impressive.